Progress in the treatment of renal anemia: Darbepoetin alfa;Fortschritte bei der therapie der renalen anämie: Darbepoetin alfa

Wiener Klinische Wochenschrift

Volumn 114, Issue 23-24, 2002, Pages 955-957

  Schaefer, Roland ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Anemia; Darbepoetin alfa; Erythropoetin; Hemoglobin; Renal anemia

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; HUMAN; KIDNEY FAILURE;

ANEMIA; CLINICAL TRIALS; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; TIME FACTORS;

EID: 0037203369     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai PH, Goldwasser E (1985) Cloning and expression of the human erythropoetin gene. Proc Natl Acad Sci USA 82: 7580-7584
2. Levin A, Foley RN (2000) Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36 [Suppl 3]: 24-30
3. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoetin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78
4. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392-2395
5. Egrie JC, Grant JR, Gillies DK, Aoki KH, Strickland TW (1993) The role of carbohydrate on the biological activity of erythropoetin. Glycoconjugate J 10: 263-268
6. Vanrenterghem Y, Barany P, Mann J, on behalf of the European/Australian NESP 970200 Study Group (1999) Novel erythropoiesis stimulating protein (NESP) maintains Hb in ESRD patients when administered once weekly or once every other week. J Am Soc Nephrol 10: 270A
7. Hörl W, Holzer H, Mayer GJ für die österreichische Aranesp Studiengruppe (2002) Behandlung der renalen Anämie mit Darbepoetin alfa - Ergebnisse einer österreichischen Multicenter-Studie. Wien Klin Wochenschr 114: 967-971
8. Locatelli F, Del Vecchio I, Marai P (2002) Clinical experience with darbepoetin alfa (Aranesp) Contrib Nephrol 137:403-407
9. Walker R (2002) Poster presented at: 11th Annual National Kidney Foundation Clinical Nephrology Meeting; April 17-21; Chicago, USA
10. Locatelli F (2002) Darbepoetin alfa unit dosing is effective for treatment of renal anemia. Nephrol Dial Transplant 17 [Suppl 1]: 136 (A)
11. Hörl W (2002) IV Darbepoetin alfa is more effective than IV rHuEPO in maintaining target Hb concentrations in patients with renal anemia. Nephrol Dial Transplant 17 [Suppl 1]: 24 (A)
12. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ (2002) Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40: 110-118
13. Haller H, für die deutsche NESP-20000111-Studiengruppe (2002) Effektivität der intravenösen Gabe von Darbepoetin alfa (Aranesp) bei Dialysepatienten mit renaler Anämie Ergebnisse aus einer multizentrischen Studie an 1502 Patienten. Nieren- und Hochdruckkrankheiten 31: 416 (A)
14. NESP 20000114 Clinical Study Report. Amgen, on file
15. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA (1998) Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339: 578-583
16. Kleophas W für die deutsche NESP-20000111-Studien-gruppe (2002) Subkutane Verabreichung von Darbepoetin alfa (Aranesp): Wirksamkeitsdaten aus einer multizentrischen Studie an 1502 Patienten mit renaler Anämie. Nieren- und Hochdruckkrankheiten 31: 413 (A)
17. Jacobs C, Hörl WH, Macdougall IC, Valderrabano F, Parrondo I, Segner A, Abraham IL (2000) European best practice guidelines 5: target hemoglobin. Nephrol Dial Transplant 15 [Suppl 4]: 15-19
18. European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure (1999) Nephrol Dial Transplant 14 [Suppl 5]: 1-50